Abstract
The mechanisms underlying Post COVID-19 condition (PCC), with its range of long-lasting symptoms, remain unclear. This study investigates DNA methylation patterns over one year in a subset of non-hospitalized COVID-19 patients with persistent symptoms and reduced quality of life, termed PCC+ (Post COVID-19 condition plus). In a cohort of 22 PCC+ individuals and 22 matched COVID-19 convalescents (PCC-), we identified distinct DNA methylation differences between the groups that diminish over time. Methylation changes in the TXNRD1 gene were significantly associated with cognitive symptoms and fatigue, implicating redox imbalance in PCC pathology. Pathway analysis revealed enrichment in PI3K-Akt and AMPK signaling pathways, potentially underlying the observed efficacy of metformin in reducing PCC incidence. While we found no differences in epigenetic age acceleration between the groups, we observed longitudinal changes in the methylation of the RAS and RAP1 signaling pathways. These findings provide crucial insights into PCC+ mechanisms and suggest oxidative stress pathways as promising targets for therapeutic interventions.
Competing Interest Statement
ML and MG are co-founders of PredictMe AB, a university spin-off company that develops DNA methylation data-based XAI disease risk classifiers.
Funding Statement
The study was supported by grants from SciLifeLab, National COVID-19 Research Program (VC-2020-0015), financed by the Knut and Alice Wallenberg Foundation, Swedish Heart-Lung Foundation (20200325, 202100789 and 20220325).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Swedish Ethical Review Authority gave ethical approval for this work (approval number: 2020-01557)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos